Daniel Ripley Net Worth

Daniel Ripley biography

Daniel L. Ripley serves as Senior Vice President - Business Development, Program and Alliance Management of the Company. Mr. Ripley previously served as our Vice President, Business Development and Program Management, since October 2014, and joined us as Senior Director, Head of Corporate Development in July 2012. Mr. Ripley has 20 years of integrated business development experience in the initiation and execution of strategic business transactions in emerging growth life science companies. He has led licensing, commercial analysis, partnering initiatives, and intellectual property enforcement to drive business development of early-to-late stage products in a wide variety of therapeutic areas and technologies. Mr. Ripley served as Senior Director of Business Development at Apricus Biosciences from 2011 through 2012, and prior to that was a senior business development consultant to biotechnology companies in the San Diego area from 2010 through 2011, Vice President of Business Development at BioBlocks, Inc. from 2009 through 2010, Senior Director, Head of Business Development at Kalypsys, Inc. from 2006 through 2008, Director of Business Development at Isis Pharmaceuticals from 2000 through 2006, and Director of Business Development at The Immune Response Corporation, Inc., from 1997 to 2000. During this timeframe, he executed multiple licensing and drug discovery collaborations with pharmaceutical and biotechnology companies that included Pfizer, Oncogenex, Alnylam, Amgen, GSK, Sanofi, and Alcon. Mr. Ripley holds an M.B.A. with an emphasis in Finance and a B.S. in Microbiology, both from San Diego State University.

How old is Daniel Ripley?

Daniel Ripley is 58, he's been the Senior Vice President - Business Development und Program and Alliance Management of Conatus Pharmaceuticals since 2017. There are 4 older and 2 younger executives at Conatus Pharmaceuticals. The oldest executive at Conatus Pharmaceuticals, Inc. is Daniel Kisner, 73, who is the Independent Director.

What's Daniel Ripley's mailing address?

Daniel's mailing address filed with the SEC is C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO, CA, 92127.

Insiders trading at Conatus Pharmaceuticals

Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over $0 worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth $17,229,485 . The most active insiders traders include Shahzad Malik, Paul H Klingenstein und Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of $47,160. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth $59,400.

What does Conatus Pharmaceuticals do?

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Conatus Pharmaceuticals executives and stock owners

Conatus Pharmaceuticals executives and other stock owners filed with the SEC include:

• Steven Mento,
  Director
• Daniel Kisner,
  Independent Director
• Hayden Yizhuo Zhang,
  Director
• Brian Satz,
  Director
• Jonathan Jackson,
  Director
• Stephen Chang,
  Director
• Thomas Hubka,
  Director of Business Operations, Corporate Secretary
• Martin Latterich,
  Vice President - Technical Operations
• Edward Smith,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• Daniel Ripley,
  Senior Vice President - Business Development, Program and Alliance Management
• Moya Daniels,
  Executive Vice President and Head of Regulatory, Quality and Clinical Operations
• Susan Knudson,
  Chief Financial Officer, Executive Vice President
• Gail Naughton,
  Founder, Chief Scientific Officer, Chief Business Officer
• Richard Pascoe,
  President, Chief Executive Officer, Director
• David Crean,
  Chairman of the Board
• William R Larue,
  Director
• Charles Cashion,
  SVP, Finance, CFO and Sec.
• Shahzad Malik,
  Director
• Alfred P. Spada,
  EVP, R&D and CSO
• David T Hagerty,
  EVP, Clinical Development
• Wart Harold Van,
  Director
• James Paul Scopa,
  Director
• Preston Klassen,
  Director
• David F Hale,
  Director
• Louis P Lacasse,
  Director
• Kathleen D. Scott,
  Director
• Keith W Marshall,
  EVP, COO & CFO
• Michelle L Vandertie,
  Vice President, Finance
• Venture Partners Llp Advent,
  10% owner
• Luke Foley Todd Gadicke Ans...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Gp Iii, L.L.C.Aberdare Vent...,
  
• Paul H Klingenstein,
  Director
• Marc Olivier Perret,
  Director
• Gilde Healthcare Ii U.A. Co...,
  10% owner
• Gary C. Burgess,
  Sr. VP, Clin. Res. & CMO